About Fasciculation and elongation protein zeta-1
Fasciculation and elongation protein zeta-1 (FEZ1) is a protein
from Homo sapiens identified by UniProt accession
Q99689, 392 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Fasciculation and elongation protein zeta-1 |
| UniProt accession | Q99689 |
| Gene | FEZ1 |
| Organism | Homo sapiens |
| Length | 392 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (69)
Diseases linked to this target (Open Targets).
- brain measurement · score 0.27
- Intellectual disability · score 0.26
- serum alanine aminotransferase measurement · score 0.23
- aspartate aminotransferase measurement · score 0.21
- platelet count · score 0.12
- drug use measurement · score 0.12
- bone measurement · score 0.09
- heel bone mineral density · score 0.08
- vital capacity · score 0.07
- mean corpuscular volume · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99689-F1 | alphafold | PREDICTED | 67.43 | — |
Amino-acid sequence (392 residues)
MEAPLVSLDE EFEDLRPSCS EDPEEKPQCF YGSSPHHLED PSLSELENFS SEIISFKSME DLVNEFDEKL NVCFRNYNAK TENLAPVKNQ LQIQEEEETL QDEEVWDALT DNYIPSLSED WRDPNIEALN GNCSDTEIHE KEEEEFNEKS ENDSGINEEP LLTADQVIEE IEEMMQNSPD PEEEEEVLEE EDGGETSSQA DSVLLQEMQA LTQTFNNNWS YEGLRHMSGS ELTELLDQVE GAIRDFSEEL VQQLARRDEL EFEKEVKNSF ITVLIEVQNK QKEQRELMKK RRKEKGLSLQ SSRIEKGNQM PLKRFSMEGI SNILQSGIRQ TFGSSGTDKQ YLNTVIPYEK KASPPSVEDL QMLTNILFAM KEDNEKVPTL LTDYILKVLC PT
Explore Fasciculation and elongation protein zeta-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets